CTIC -- 7/4/99





-- Access Pharmaceuticals -- ACTV -- Advanced Tissue Sciences, Inc. -- AMBI Inc. -- ARIAD Pharmaceuticals, Inc. -- Cell Therapeutics, Inc. + Video 07-01-99 + Update 06-01-99 + Full-Length Initial Opinion + Financial Model + Initial Opinion -- CTC Communications -- Cubist Pharmaceuticals, Inc. -- Cypress Bioscience -- CytRx Corp. -- Exigent International, Inc. -- FutureLink Distribution Corp. -- Hemacare Corporation -- Medarex, Inc. -- Valentis, Inc.

To receive immediate notification of research updates, enter your e-mail address here (ex: name@domain.com):

Wall Street Interview with Dr. Bianco, President of CTIC.

Dr. James Bianco President & CEO		Cell Therapeutics, Inc. (Nasdaq:CTIC) 201 Elliott Ave W Ste 400, Seattle WA 98119-4230 Phone: 206-282-7100 Fax: 206-284-6206 www.cticseattle.com

If you do not have RealPlayer G2,
please download it here .

cti

is a specialty pharmaceutical company that focuses on the discovery, development and commercialization of small-molecule drugs for the treatment of cancer and immune diseases.

We are building a vertically-integrated portfolio of products that leverage our lead compounds, our platform of novel technologies and our global partnerships, which capitalize on a wide world of scientific, financial and marketing relationships.

Our mission: To build a profitable U.S.-based, vertically integrated pharmaceutical company by developing drugs that improve the quality of life for patients with cancer and immune disease.

(Courtesy of Wall Street Inverview -- www.wallstreetinterview.com)